Market Closed -
Euronext Paris
11:35:13 2024-05-07 am EDT
|
After market
12:09:23 pm
|
6.215
EUR
|
+2.98%
|
|
6.22
|
+0.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
185
|
475.1
|
254.5
|
126.2
|
284.3
|
-
|
-
|
Enterprise Value (EV)
1 |
194.5
|
404.9
|
216.6
|
137.9
|
308.7
|
312.4
|
284.3
|
P/E ratio
|
-3.52
x
|
-9.86
x
|
-5.41
x
|
-2.21
x
|
-7.97
x
|
-15.5
x
|
-8.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
72.8
x
|
189
x
|
96.1
x
|
26.4
x
|
12.5
x
|
7.3
x
|
7.98
x
|
EV / Revenue
|
76.5
x
|
161
x
|
81.8
x
|
28.9
x
|
13.5
x
|
8.02
x
|
7.98
x
|
EV / EBITDA
|
-4.32
x
|
-11.7
x
|
-4.24
x
|
-
|
-6.95
x
|
-5.83
x
|
-4.86
x
|
EV / FCF
|
-4.6
x
|
-14.7
x
|
-
|
-3.71
x
|
-9.26
x
|
-7.56
x
|
-
|
FCF Yield
|
-21.7%
|
-6.82%
|
-
|
-27%
|
-10.8%
|
-13.2%
|
-
|
Price to Book
|
-97.3
x
|
-
|
-
|
-
|
-3.7
x
|
-2.81
x
|
-
|
Nbr of stocks (in thousands)
|
22,347
|
34,427
|
34,811
|
34,850
|
47,111
|
-
|
-
|
Reference price
2 |
8.280
|
13.80
|
7.310
|
3.620
|
6.035
|
6.035
|
6.035
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.541
|
2.512
|
2.647
|
4.776
|
22.82
|
38.96
|
35.62
|
EBITDA
1 |
-45.01
|
-34.67
|
-51.02
|
-
|
-44.4
|
-53.58
|
-58.5
|
EBIT
1 |
-46.78
|
-36.43
|
-52.58
|
-46.7
|
-38.21
|
-44.81
|
-28.96
|
Operating Margin
|
-1,840.97%
|
-1,450.16%
|
-1,986.36%
|
-977.85%
|
-167.5%
|
-115.02%
|
-81.3%
|
Earnings before Tax (EBT)
1 |
-50.91
|
-33.58
|
-47
|
-57.03
|
-45.92
|
-58.63
|
-33.47
|
Net income
1 |
-50.92
|
-33.59
|
-47
|
-57.04
|
-40.88
|
-31.46
|
-33.47
|
Net margin
|
-2,003.74%
|
-1,337.18%
|
-1,775.71%
|
-1,194.33%
|
-179.16%
|
-80.76%
|
-93.97%
|
EPS
2 |
-2.350
|
-1.400
|
-1.350
|
-1.640
|
-0.7575
|
-0.3900
|
-0.6850
|
Free Cash Flow
1 |
-42.26
|
-27.63
|
-
|
-37.2
|
-33.35
|
-41.3
|
-
|
FCF margin
|
-1,663.12%
|
-1,100.08%
|
-
|
-778.81%
|
-146.18%
|
-106.01%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 S1
|
2022 S2
|
2023 S1
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
|
0.718
|
1.448
|
1.064
|
1.319
|
-
|
-
|
1.329
|
3.447
|
3.293
|
21.23
|
12.2
|
16
|
21.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-24.63
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.31
|
-18.38
|
-18.04
|
-29.78
|
-14.11
|
-14.11
|
-25.88
|
-20.82
|
-25.37
|
-9.4
|
-29.3
|
-
|
-
|
Operating Margin
|
-3,664.62%
|
-1,269.61%
|
-1,695.86%
|
-2,257.62%
|
-
|
-
|
-1,947.1%
|
-604.15%
|
-770.42%
|
-44.27%
|
-240.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-26.99
|
-20.58
|
-13
|
-30.42
|
-8.29
|
-8.29
|
-26.35
|
-30.68
|
-28.1
|
-11.2
|
-31.1
|
-
|
-
|
Net income
1 |
-27
|
-20.58
|
-13.01
|
-30.42
|
-8.29
|
-8.29
|
-26.36
|
-30.68
|
-28.1
|
-15
|
-25.4
|
-
|
-
|
Net margin
|
-3,759.75%
|
-1,421.2%
|
-1,222.84%
|
-2,306.29%
|
-
|
-
|
-1,983.22%
|
-890.17%
|
-853.29%
|
-70.64%
|
-208.2%
|
-
|
-
|
EPS
|
-1.200
|
-0.9100
|
-0.4900
|
-0.8800
|
-
|
-
|
-0.7600
|
-
|
-0.8000
|
-0.2667
|
-0.5000
|
-0.3800
|
-0.2700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/20
|
9/4/20
|
3/17/21
|
9/8/21
|
4/8/22
|
3/30/22
|
9/28/22
|
4/24/23
|
9/26/23
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
9.43
|
-
|
-
|
11.8
|
24.4
|
28.1
|
-
|
Net Cash position
1 |
-
|
70.2
|
37.9
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.2095
x
|
-
|
-
|
-
|
-0.5484
x
|
-0.5235
x
|
-
|
Free Cash Flow
1 |
-42.3
|
-27.6
|
-
|
-37.2
|
-33.4
|
-41.3
|
-
|
ROE (net income / shareholders' equity)
|
-826%
|
-98%
|
-96.7%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-0.0900
|
-
|
-
|
-
|
-1.630
|
-2.150
|
-
|
Cash Flow per Share
2 |
-1.900
|
-1.130
|
-0.8600
|
-
|
-0.7100
|
-0.6600
|
-
|
Capex
1 |
1.09
|
0.1
|
0.23
|
0.09
|
0.91
|
0.57
|
0.2
|
Capex / Sales
|
42.94%
|
3.82%
|
8.61%
|
1.93%
|
3.97%
|
1.47%
|
0.56%
|
Announcement Date
|
3/17/20
|
3/17/21
|
3/30/22
|
4/24/23
|
-
|
-
|
-
|
Last Close Price
6.035
EUR Average target price
10.6
EUR Spread / Average Target +75.64% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.74% | 306M | | +22.81% | 46.81B | | +46.73% | 41.29B | | -1.88% | 41.37B | | -6.20% | 28.87B | | +11.33% | 26.06B | | -21.00% | 19.13B | | -1.43% | 11.96B | | +30.73% | 12.39B | | -0.48% | 12.08B |
Other Biotechnology & Medical Research
|